10x Genomics/$TXG
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About 10x Genomics
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
- Ticker
- $TXG
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,178
- Headquarters
- Pleasanton, United States
- Website
- www.10xgenomics.com
10x Genomics Metrics
BasicAdvanced
$8.3B
-
-$0.52
2.03
-
Price and volume
Market cap
$8.3B
Beta
2.03
52-week high
$102.81
52-week low
$15.12
Average daily volume
3.9M
Financial strength
Current ratio
5.12
Quick ratio
4.52
Long term debt to equity
0.076
Total debt to equity
0.09
Profitability
EBITDA (TTM)
-25.942
Gross margin (TTM)
71.96%
Net profit margin (TTM)
-10.84%
Operating margin (TTM)
-10.51%
Effective tax rate (TTM)
-2.94%
Revenue per employee (TTM)
$530,000
Management effectiveness
Return on assets (TTM)
-3.89%
Return on equity (TTM)
-8.27%
Valuation
Price to revenue (TTM)
13.113
Price to book
9.82
Price to tangible book (TTM)
10.65
Price to free cash flow (TTM)
86.5
Free cash flow yield (TTM)
1.16%
Free cash flow per share (TTM)
0.727
Growth
Revenue change (TTM)
-3.62%
Earnings per share change (TTM)
-15.91%
3-year revenue growth (CAGR)
1.53%
3-year earnings per share growth (CAGR)
-35.32%
What the Analysts think about 10x Genomics
Analyst ratings (Buy, Hold, Sell) for 10x Genomics stock.
Analyst projections of the future price of 10x Genomics stock.
Bulls say / Bears say
Atera could become a meaningful new growth engine: by late September, 10x said booked orders already exceeded its 2026 shipment plan of 40 units, and it had begun commercial shipments. (Nasdaq)
Recurring consumables demand is holding up better than instrument placements: Q2 consumables revenue rose 7% year on year, led by 16% growth in spatial consumables. (SEC)
The Proteintech Genomics acquisition broadens 10x’s multiomics offer with advanced protein-detection capabilities, giving its single-cell and spatial platforms a wider range of measurements. (PR Newswire)
Customers waiting for Atera are already suppressing legacy sales: Q2 instrument revenue fell 47% year on year, and management expected a sequential revenue decline in Q3 as the product transition continued. (SEC, The Motley Fool)
Underlying growth remains weak and research budgets are a drag: management forecast only 2%–5% full-year revenue growth excluding settlements and said academic funding was not yet translating into customer spending. (PR Newswire, The Motley Fool)
Profitability remains elusive: 10x posted a $19.6 million operating loss in Q2 and said it expects to keep recording operating losses for the foreseeable future. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2026.
10x Genomics Financial Performance
Revenues and expenses
10x Genomics Earnings Performance
Company profitability
Upcoming events
No upcoming events
10x Genomics News
AllArticlesVideos
Funds containing 10x Genomics
AllUSDEURGBP
Fund name | Fund size | $TXG weighting |
|---|---|---|
ARK Genomic Revolution£ARCG | $123M | 6.40% |
ARK Genomic Revolution€AAKG | $123M | 6.40% |
ARK Innovation€ARXK | $325M | 2.87% |
ARK Innovation£ARCK | $325M | 2.87% |
iShares Healthcare Innovation£DRDR | $1.3B | 0.73% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.